Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Sep;40(3):209–215.

Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer.

R M Mader 1, G G Steger 1, B Rizovski 1, M P Djavanmard 1, W Scheithauer 1, R Jakesz 1, H Rainer 1
PMCID: PMC1365099  PMID: 8527281

Abstract

1. The pharmacokinetics and toxicity of racemic 5-methyltetrahydrofolic (rac-5-MTHF) acid after i.v. infusion were investigated in 18 patients with advanced colorectal cancer. Doses of 100-600 mg rac-5-MTHF/m2 were administered over 2 h together with a bolus of 500 mg/m2 5-fluorouracil (5-FU) as a midpoint injection. 2. The pharmacokinetics of both diastereoisomers were linear in the range from 100-600 mg 5-MTFH/m2. Independent of the administered dose, the maximal plasma concentration of [R]-5-MTHF was nearly twice that of [S]-5-MTHF. The elimination of [S]-5-MTHF from plasma was considerably faster than that of the [R]-isomer (elimination half-life: 3.1 +/- 1.0 h vs 8.3 +/- 3.2 h). No metabolites were detected in plasma and in urine samples. 3. The plasma protein binding was stereoselective ([R]-5-MTHF bound: 88.2 +/- 2.7%; [S]-5-MTHF bound: 59.9 +/- 6.8%; P < 0.001), causing a significantly higher renal clearance for [S]-5-MTHF when compared with the [R]-isomer (37.5 +/- 23.7 ml min-1 vs 12.7 +/- 11.2 ml min-1, P < 0.001). There was no dose dependence, but gender influenced renal clearance (CLren[R]-5-MTHF: male vs female: 20.5 +/- 14.5 ml min-1 vs 7.8 +/- 4.7 min-1, P = 0.03; CLren [S]-5-MTHF: male vs female: 57.2 +/- 21.7 ml min-1 vs 25.7 +/- 16.2 ml min-1, P = 0.006). 4. Toxic side effects of the combination 5-FU/5-MTHF were rare and generally mild, and included stomatitis, nausea/emesis, diarrhoea, anaemia, leukopenia, and thrombocytopenia. 5. In combination with 500 mg 5-FU/m2 a single dose of 600 mg rac-5-MTHF/m2 can safely be administered to patients with colorectal cancer. A similar therapeutic benefit of 5-MTHF to folinic acid in the biochemical modulation of 5-FU is supported by the comparison of in vitro and in vivo data.

Full text

PDF
212

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernabei P. A., Bensinger W. I. Effect of (dl)-5-methyltetrahydrofolate on lymphoid leukemia cell lines. Leuk Res. 1991;15(7):645–649. doi: 10.1016/0145-2126(91)90034-q. [DOI] [PubMed] [Google Scholar]
  2. Casali A., Tonachella R., Tropea F., Verri C., Paoletti G., Gionfra T., Modugno G., Gallo Curcio C. Treatment of advanced colorectal and gastric cancer with 5-fluorouracil and calcium n-methyltetrahydrofolate. J Chemother. 1989 Jul;1(4 Suppl):1212–1214. [PubMed] [Google Scholar]
  3. Choi K. E., Schilsky R. L. Resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate by chiral high-performance liquid chromatography. Anal Biochem. 1988 Feb 1;168(2):398–404. doi: 10.1016/0003-2697(88)90335-1. [DOI] [PubMed] [Google Scholar]
  4. Etienne M. C., Fischel J. L., Formento P., Schneider M., Guillot T., Bardon M., Milano G. Combination of reduced folates with methotrexate or 5-fluorouracil. Comparison between 5-formyltetrahydrofolate (folinic acid) and 5-methyltetrahydrofolate in vitro activities. Biochem Pharmacol. 1993 Nov 17;46(10):1767–1774. doi: 10.1016/0006-2952(93)90581-g. [DOI] [PubMed] [Google Scholar]
  5. Goldsmith M. A., Slavik M., Carter S. K. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res. 1975 May;35(5):1354–1364. [PubMed] [Google Scholar]
  6. Houghton J. A., Williams L. G., Loftin S. K., Cheshire P. J., Morton C. L., Houghton P. J., Dayan A., Jolivet J. Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts. Cancer Chemother Pharmacol. 1992;30(6):423–432. doi: 10.1007/BF00685592. [DOI] [PubMed] [Google Scholar]
  7. Houghton J. A., Williams L. G., de Graaf S. S., Cheshire P. J., Rodman J. H., Maneval D. C., Wainer I. W., Jadaud P., Houghton P. J. Relationship between dose rate of [6RS]Leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res. 1990 Jun 15;50(12):3493–3502. [PubMed] [Google Scholar]
  8. Kane M. A., Roth E., Raptis G., Schreiber C., Waxman S. Effect of intracellular folate concentration on the modulation of 5-fluorouracil cytotoxicity by the elevation of phosphoribosylpyrophosphate in cultured human KB cells. Cancer Res. 1987 Dec 15;47(24 Pt 1):6444–6450. [PubMed] [Google Scholar]
  9. Mader R. M., Steger G. G., Rizovski B., Jakesz R., Rainer H. Different stereospecific protein binding of tetrahydrofolates to human serum albumin. J Pharm Sci. 1994 Sep;83(9):1247–1249. doi: 10.1002/jps.2600830912. [DOI] [PubMed] [Google Scholar]
  10. Mader R. M., Steger G. G., Rizovski B., Sieder A. E., Locker G., Gnant M. F., Jakesz R., Rainer H. Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer. Br J Clin Pharmacol. 1994 Mar;37(3):243–248. doi: 10.1111/j.1365-2125.1994.tb04270.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. McGuire B. W., Sia L. L., Leese P. T., Gutierrez M. L., Stokstad E. L. Pharmacokinetics of leucovorin calcium after intravenous, intramuscular, and oral administration. Clin Pharm. 1988 Jan;7(1):52–58. [PubMed] [Google Scholar]
  12. Mehta B. M., Glass J. P., Shapiro W. R. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya methotrexate administration in patients with meningeal carcinomatosis. Cancer Res. 1983 Jan;43(1):435–438. [PubMed] [Google Scholar]
  13. Mini E., Mazzei T., Coronnello M., Criscuoli L., Gualtieri M., Periti P., Bertino J. R. Effects of 5-methyltetrahydrofolate on the activity of fluoropyrimidines against human leukemia (CCRF-CEM) cells. Biochem Pharmacol. 1987 Sep 15;36(18):2905–2911. doi: 10.1016/0006-2952(87)90201-2. [DOI] [PubMed] [Google Scholar]
  14. Newman E. M., Straw J. A., Doroshow J. H. Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. Cancer Res. 1989 Oct 15;49(20):5755–5760. [PubMed] [Google Scholar]
  15. Nobile M. T., Sertoli M. R., Bruzzone M., Tagarelli G., Rubagotti A., Rosso R. Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer. Eur J Cancer Clin Oncol. 1985 Oct;21(10):1175–1177. doi: 10.1016/0277-5379(85)90011-2. [DOI] [PubMed] [Google Scholar]
  16. Reggev A., Djerassi I. Rescue from high-dose methotrexate with 5-methyltetrahydrofolate. Cancer Treat Rep. 1986 Feb;70(2):251–253. [PubMed] [Google Scholar]
  17. Schalhorn A., Kühl M., Stupp-Poutot G., Nüssler V. Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. Cancer Chemother Pharmacol. 1990;25(6):440–444. doi: 10.1007/BF00686056. [DOI] [PubMed] [Google Scholar]
  18. Schilsky R. L., Ratain M. J. Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. J Natl Cancer Inst. 1990 Sep 5;82(17):1411–1415. doi: 10.1093/jnci/82.17.1411. [DOI] [PubMed] [Google Scholar]
  19. Schmitz J. C., Stuart R. K., Priest D. G. Disposition of folic acid and its metabolites: a comparison with leucovorin. Clin Pharmacol Ther. 1994 May;55(5):501–508. doi: 10.1038/clpt.1994.63. [DOI] [PubMed] [Google Scholar]
  20. Shumaker R. C. PKCALC: a BASIC interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev. 1986;17(3-4):331–348. doi: 10.3109/03602538608998295. [DOI] [PubMed] [Google Scholar]
  21. Thyss A., Milano G., Etienne M. C., Paquis P., Roche J. L., Grelier P., Schneider M. Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue. Br J Cancer. 1989 Apr;59(4):627–630. doi: 10.1038/bjc.1989.127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Trave F., Rustum Y. M., Petrelli N. J., Herrera L., Mittelman A., Frank C., Creaven P. J. Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. J Clin Oncol. 1988 Jul;6(7):1184–1191. doi: 10.1200/JCO.1988.6.7.1184. [DOI] [PubMed] [Google Scholar]
  23. van der Wilt C. L., Pinedo H. M., de Jong M., Peters G. J. Effect of folate diastereoisomers on the binding of 5-fluoro-2'-deoxyuridine-5'-monophosphate to thymidylate synthase. Biochem Pharmacol. 1993 Mar 9;45(5):1177–1179. doi: 10.1016/0006-2952(93)90267-z. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES